Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Management of Pituitary Tumors
Ann Int Med 129:472-483, Shimon,I.&Melmed,S., 1998
Long-Term Octreotide Therapy in Growth Hormone-Secreting Pituitary Adenomas:Evaluation with Serial MR
AJNR 18:765-772, Lundin,P.,et al, 1997
Octreotide
NEJM 334:246-254, Lamberts,S.W.J.,et al, 1996
Diagnosis and Management of Pituitary Tumours
BMJ 308:1087-1091, Levy,A.&Lightman,S.L., 1994
Consensus Statement:Benefits VS Risk of Medical Therapy for Acromegaly
Am J Med 97:468-473, Melmed,S.,et al, 1994
Octreotide Therapy for Thyroid-Stimulation Hormone-Secreting Pituitary Adenomas, A Follow-up of 52 Patients
Ann Int Med 119:236-240, Chanson,P.,et al, 1993
Acromegaly:Treatment After 100 Years
BMJ 307:1505-1506, Wass,J.A.H., 1993
Octreotide Treatment of Acromegaly, A Randomized, Multicenter Study
Ann Int Med 117:711-718, Ezzat,S.,et al, 1992
Long-term Treatment of 189 Acromegalic Patients with the Somatostatin Analog Octreotide
Arch Int Med 151:1573-1578, Vance,M.L.&Harris,A.G., 1991
Reversal of a Neurologic Paraneoplastic Syndrome with Octreotide (Sandostatin) in a Pt with Glucagonoma
Am J Med 91:434-436, Holmes,A.,et al, 1991
Acromegaly
NEJM 322:966-977, Melmed,S., 1990
Response of Thyrotropin-Secreting Pituitary Adenomas to a Long-Acting Somatostatin Analogue
NEJM 317:12-17, Comi,R.J.,et al, 1987
Visual Improvement with SMS 201-995 in a Patient with a Thyrotropin-Secreting Pituitary Adenoma
NEJM 317:53-54, Guillaussea,P.J.,et al, 1987
Effective & Lasting Growth-Hormone Suppres in Active Acromegaly with Oral Admin of Somatostatin Analogue SMS 201-995
Lancet 2:774-778, Williams,G.,et al, 1986
Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201-995
NEJM 313:1576-1580, 1604-16051985., Lamberts,S.W.J.,et al, 1985